CIK 0001604821
- Large accelerated filer
Natera, Inc.
Sign in to watch- Ticker
- NTRA
- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 010894487
- Phone
- +1 650-249-9090
- Business address
- 13011 MCCALLEN PASS, BUILDING A SUITE 100, AUSTIN, TX, 78753
- Former names
- Natera, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $104,832,418
- in 28 filings, $104.8M under 10b5-1 plans
Net −$104,832,418. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Rabinowitz Matthew −$72.3M EXECUTIVE CHAIRMAN sold 9% of stake
- Sheena Jonathan −$13.8M Director sold 83% of stake
- Moshkevich Solomon −$9.5M PRESIDENT, CLINICALDIAGNOSTICS sold 21% of stake
- Chapman Steven Leonard −$5.0M CEO AND PRESIDENT sold 12% of stake
- Brophy Michael Burkes −$2.5M CHIEF FINANCIAL OFFICER sold 11% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-12-02 | BOTHA ROELOF Director | Sale | −11,219 | $170.54 | $1.9M | 1,224,787 |
| 2024-11-26 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −660 | $163.25 | $108K | 85,340 |
| 2024-11-26 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −940 | $164.24 | $154K | 84,400 |
| 2024-11-26 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −400 | $165.55 | $66K | 84,000 |
| 2024-11-25 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −1,089 | $167.89 | $183K | 86,911 |
| 2024-11-25 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −600 | $168.91 | $101K | 86,311 |
| 2024-11-25 | Rabinowitz Matthew EXECUTIVE CHAIRMAN | Sale 10b5-1 | −311 | $169.94 | $53K | 86,000 |
| 2024-11-19 | Marcus Gail Boxer Director | Sale | −7,582 | $159.83 | $1.2M | 11,804 |
| 2024-11-19 | Marcus Gail Boxer Director | Sale | −2,100 | $160.52 | $337K | 9,704 |
| 2024-11-15 | Baynes Roy D. Director | Exercise or conversion 10b5-1 | +22,000 | $22.83 | $502K | 37,807 |
| 2024-11-15 | Baynes Roy D. Director | Exercise or conversion 10b5-1 | +15,230 | $24.42 | $372K | 53,037 |
| 2024-11-15 | Baynes Roy D. Director | Sale 10b5-1 | −5,500 | $144.26 | $793K | 47,537 |
| 2024-11-15 | Baynes Roy D. Director | Sale 10b5-1 | −16,404 | $145.21 | $2.4M | 31,133 |
| 2024-11-15 | Baynes Roy D. Director | Sale 10b5-1 | −1,770 | $146.26 | $259K | 29,363 |
| 2024-11-15 | Baynes Roy D. Director | Sale 10b5-1 | −9,467 | $147.31 | $1.4M | 19,896 |
| 2024-11-15 | Baynes Roy D. Director | Sale 10b5-1 | −2,106 | $148.74 | $313K | 17,790 |
| 2024-11-15 | Baynes Roy D. Director | Sale 10b5-1 | −1,983 | $149.98 | $297K | 15,807 |
| 2024-11-15 | Baynes Roy D. Director | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −22,000 | 0 | ||
| 2024-11-15 | Baynes Roy D. Director | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −15,230 | 0 | ||
| 2024-11-15 | Chapman Steven Leonard CEO AND PRESIDENT | Sale 10b5-1 | −985 | $144.44 | $142K | 188,777 |
Page 62 of 85 · 1,682 trades